大行评级|大摩:大幅上调默沙东目标价至89美元,评级升至“增持”

格隆汇
Aug 20
摩根士丹利将默沙东的目标价从39美元上调至89美元,评级从“持有”上调至“增持”,鉴于个性化黑色素瘤疫苗intismeran autogene试验成功,公司如今更有能力应对其重磅疗法Keytruda在2028年面临的专利悬崖。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10